Total Payments
$5.0M
2024 Payments
$581,176
Companies
68
Transactions
3,498
Medicare Patients
11,000
Medicare Billing
$2.8M
Payment Breakdown by Category
Other$3.6M (72.2%)
Consulting$821,479 (16.3%)
Travel$422,183 (8.4%)
Research$103,786 (2.1%)
Food & Beverage$50,574 (1.0%)
Education$164.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 905 | 67.4% |
| Consulting Fee | $821,479 | 173 | 16.3% |
| Travel and Lodging | $422,183 | 1,308 | 8.4% |
| Honoraria | $219,601 | 62 | 4.4% |
| Unspecified | $103,786 | 44 | 2.1% |
| Food and Beverage | $50,574 | 990 | 1.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $20,080 | 6 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.0% |
| Education | $164.17 | 9 | 0.0% |
Payments by Type
General
$4.9M
3,454 transactions
Research
$103,786
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $1.0M | 158 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $613,458 | 400 | $0 (2024) |
| ABBVIE INC. | $336,968 | 299 | $0 (2024) |
| BeiGene USA, Inc. | $292,235 | 212 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $286,789 | 228 | $0 (2024) |
| Incyte Corporation | $258,499 | 259 | $0 (2024) |
| Amgen Inc. | $196,131 | 198 | $0 (2024) |
| SOBI, INC | $190,167 | 117 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $170,316 | 138 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $152,037 | 147 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $581,176 | 508 | E.R. Squibb & Sons, L.L.C. ($106,345) |
| 2023 | $821,925 | 678 | Seagen Inc. ($101,986) |
| 2022 | $1.1M | 641 | Seagen Inc. ($398,785) |
| 2021 | $1.1M | 494 | Seagen Inc. ($504,525) |
| 2020 | $389,741 | 263 | Takeda Pharmaceuticals U.S.A., Inc. ($64,693) |
| 2019 | $501,718 | 391 | Takeda Pharmaceuticals U.S.A., Inc. ($149,183) |
| 2018 | $396,865 | 360 | Takeda Pharmaceuticals U.S.A., Inc. ($168,793) |
| 2017 | $166,223 | 163 | Millennium Pharmaceuticals, Inc. ($44,618) |
All Payment Transactions
3,498 individual payment records from CMS Open Payments — Page 1 of 140
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: ONCOLOGY | ||||||
| 12/26/2024 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,864.00 | General |
| Category: Oncology | ||||||
| 12/26/2024 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $644.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Amgen Inc. | Kyprolis (Drug) | Travel and Lodging | In-kind items and services | $683.41 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Amgen Inc. | Kyprolis (Drug) | Travel and Lodging | Cash or cash equivalent | $30.82 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Amgen Inc. | Kyprolis (Drug) | Travel and Lodging | Cash or cash equivalent | $6.80 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,480.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,082.00 | General |
| 12/11/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/11/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $7.35 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $272.50 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $245.71 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $129.24 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $121.18 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,864.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $53.71 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $37,322 | 6 |
| A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | PFIZER INC. | $20,584 | 3 |
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $11,711 | 7 |
| ISB 1342-101 | IGI Inc | $10,426 | 2 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,330 | 16 |
| CABL001AUS04 | Novartis Pharmaceuticals Corporation | $4,351 | 1 |
| CABL001AUS08 | Novartis Pharmaceuticals Corporation | $4,273 | 3 |
| AN OPEN LABEL, MULTI-CENTER PHASE IIIB STUDY OF ASCIMINIB (ABL001) MONOTHERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA ON CHRONIC PHASE (CML-CP) PREVIOUSLY TREATED WITH AT LEAST 2 PRIOR TKIS (TYROSINE KINASE INHIBITORS) | Novartis Pharmaceuticals Corporation | $2,160 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,073 | 2 |
| A PHASE I OPEN LABEL STUDY TO EVALUATE THE SAFETY PHARMACOKINETIC PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSEDREFRACTORY ADVANCED MULTIPLE MYELOMA MM | PFIZER INC. | $286.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 2,315 | 35,628 | $2.4M | $578,893 |
| 2022 | 49 | 2,513 | 46,329 | $2.2M | $501,352 |
| 2021 | 58 | 3,146 | 64,843 | $3.2M | $704,776 |
| 2020 | 59 | 3,026 | 55,492 | $4.2M | $1.0M |
Total Patients
11,000
Total Services
202,292
Medicare Billing
$2.8M
Procedure Codes
214
All Medicare Procedures & Services
214 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 6,900 | $936,500 | $294,689 | 31.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 3,060 | $388,440 | $115,886 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 487 | $179,216 | $47,014 | 26.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 7,260 | $145,200 | $17,241 | 11.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 116 | 165 | $116,655 | $17,174 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 119 | 174 | $43,500 | $10,812 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 56 | $27,776 | $7,924 | 28.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 198 | 667 | $42,688 | $6,903 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 205 | 636 | $12,720 | $5,342 | 42.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $23,397 | $5,333 | 22.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 79 | 189 | $29,673 | $4,317 | 14.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 23 | 24 | $25,608 | $4,237 | 16.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 193 | 544 | $19,584 | $4,140 | 21.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 37 | 65 | $22,360 | $3,299 | 14.8% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 29 | 188 | $11,280 | $3,182 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 47 | $11,609 | $2,926 | 25.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 31 | $11,067 | $2,903 | 26.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 42 | 50 | $15,650 | $2,513 | 16.1% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 34 | 70 | $10,010 | $2,452 | 24.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 25 | 42 | $8,862 | $2,449 | 27.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 56 | 179 | $10,740 | $2,391 | 22.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 72 | 135 | $14,580 | $1,655 | 11.4% |
| 83550 | Iron binding capacity | Office | 2023 | 54 | 172 | $6,020 | $1,474 | 24.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 26 | 27 | $22,167 | $1,285 | 5.8% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 13 | 141 | $7,896 | $1,285 | 16.3% |
About Dr. Moshe Levy, MD
Dr. Moshe Levy, MD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518059807.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Moshe Levy, MD has received a total of $5.0M in payments from pharmaceutical and medical device companies, with $581,176 received in 2024. These payments were reported across 3,498 transactions from 68 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.4M).
As a Medicare-enrolled provider, Levy has provided services to 11,000 Medicare beneficiaries, totaling 202,292 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 214 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Dallas, TX
- Active Since 09/28/2006
- Last Updated 09/01/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1518059807
Products in Payments
- ADCETRIS (Biological) $1.2M
- ICLUSIG (Drug) $403,269
- BRUKINSA (Drug) $291,335
- MONJUVI (Drug) $256,863
- NINLARO (Drug) $215,188
- Venclexta (Drug) $194,877
- XPOVIO (Drug) $170,316
- REBLOZYL (Biological) $168,359
- Doptelet (Drug) $166,746
- CALQUENCE (Drug) $147,472
- Kyprolis (Drug) $133,995
- DARZALEX (Biological) $114,720
- VENCLEXTA (Drug) $93,754
- TAZVERIK (Drug) $78,741
- Pomalyst (Drug) $74,935
- Revlimid (Drug) $74,526
- DOPTELET (Drug) $70,478
- BLENREP (Biological) $64,211
- Yescarta (Drug) $61,849
- VYXEOS (Drug) $61,724
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262
Dr. Stephen Jones, Md, MD
Medical Oncology — Payments: $221,960
Medical Oncology $221,960